U.S. Markets close in 5 hrs 21 mins
  • S&P 500

    3,418.35
    -47.04 (-1.36%)
     
  • Dow 30

    27,818.71
    -516.86 (-1.82%)
     
  • Nasdaq

    11,460.51
    -87.77 (-0.76%)
     
  • Russell 2000

    1,616.89
    -23.61 (-1.44%)
     
  • Crude Oil

    38.56
    -1.29 (-3.24%)
     
  • Gold

    1,906.30
    +1.10 (+0.06%)
     
  • Silver

    24.50
    -0.17 (-0.69%)
     
  • EUR/USD

    1.1819
    -0.0049 (-0.4137%)
     
  • 10-Yr Bond

    0.8110
    -0.0300 (-3.57%)
     
  • Vix

    29.41
    +1.86 (+6.75%)
     
  • GBP/USD

    1.3007
    -0.0031 (-0.2393%)
     
  • USD/JPY

    104.9580
    +0.2680 (+0.2560%)
     
  • BTC-USD

    13,181.59
    +104.58 (+0.80%)
     
  • CMC Crypto 200

    263.39
    -0.02 (-0.01%)
     
  • FTSE 100

    5,842.67
    -17.61 (-0.30%)
     
  • Nikkei 225

    23,494.34
    -22.25 (-0.09%)
     

Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrophin, Inc.
·2 mins read

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,750 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 37,500 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 21,250 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Retrophin’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Retrophin in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $20.68 per share, the closing price of Retrophin’s common stock on the next trading day following the date of grant, are non-qualified stock options, have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates.

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates.

About Retrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.

Retrophin.com

Contact:

Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@retrophin.com